185 related articles for article (PubMed ID: 34826603)
1. Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-β1 pathway: therapeutic role of roflumilast.
Tao X; He H; Peng J; Xu R; Fu J; Hu Y; Li L; Yang X; Feng X; Zhang C; Zhang L; Yu X; Shen A; Huang K; Fu Q
Pharmacol Res; 2022 Jan; 175():106004. PubMed ID: 34826603
[TBL] [Abstract][Full Text] [Related]
2. Genetic deletion of phosphodiesterase 4D in the liver improves kidney damage in high-fat fed mice: liver-kidney crosstalk.
Tao X; Chen C; Huang Z; Lei Y; Wang M; Wang S; Tian D
Cell Death Dis; 2023 Apr; 14(4):273. PubMed ID: 37072403
[TBL] [Abstract][Full Text] [Related]
3. Roflumilast-Mediated Phosphodiesterase 4D Inhibition Reverses Diabetes-Associated Cardiac Dysfunction and Remodeling: Effects Beyond Glucose Lowering.
Xu R; Fu J; Hu Y; Yang X; Tao X; Chen L; Huang K; Fu Q
Diabetes; 2022 Aug; 71(8):1660-1678. PubMed ID: 35594380
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiestrase-1 and 4 inhibitors ameliorate liver fibrosis in rats: Modulation of cAMP/CREB/TLR4 inflammatory and fibrogenic pathways.
Essam RM; Ahmed LA; Abdelsalam RM; El-Khatib AS
Life Sci; 2019 Apr; 222():245-254. PubMed ID: 30858122
[TBL] [Abstract][Full Text] [Related]
5. PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts.
Togo S; Liu X; Wang X; Sugiura H; Kamio K; Kawasaki S; Kobayashi T; Ertl RF; Ahn Y; Holz O; Magnussen H; Fredriksson K; Skold CM; Rennard SI
Am J Physiol Lung Cell Mol Physiol; 2009 Jun; 296(6):L959-69. PubMed ID: 19304913
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the therapeutic index of a novel phosphodiesterase 4B-selective inhibitor over phosphodiesterase 4D in mice.
Suzuki O; Mizukami K; Etori M; Sogawa Y; Takagi N; Tsuchida H; Morimoto K; Goto T; Yoshino T; Mikkaichi T; Hirahara K; Nakamura S; Maeda H
J Pharmacol Sci; 2013; 123(3):219-26. PubMed ID: 24152964
[TBL] [Abstract][Full Text] [Related]
7. The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation.
Konrad FM; Bury A; Schick MA; Ngamsri KC; Reutershan J
PLoS One; 2015; 10(4):e0121725. PubMed ID: 25909327
[TBL] [Abstract][Full Text] [Related]
8. The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism.
Möllmann J; Kahles F; Lebherz C; Kappel B; Baeck C; Tacke F; Werner C; Federici M; Marx N; Lehrke M
Diabetes Obes Metab; 2017 Apr; 19(4):496-508. PubMed ID: 27917591
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-137-3p Improves Nonalcoholic Fatty Liver Disease through Activating AMPK
Yu Y; He C; Tan S; Huang M; Guo Y; Li M; Zhang Q
Anal Cell Pathol (Amst); 2021; 2021():4853355. PubMed ID: 35004133
[TBL] [Abstract][Full Text] [Related]
10. PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner.
Lehrke M; Kahles F; Makowska A; Tilstam PV; Diebold S; Marx J; Stöhr R; Hess K; Endorf EB; Bruemmer D; Marx N; Findeisen HM
J Mol Cell Cardiol; 2015 Apr; 81():23-33. PubMed ID: 25640159
[TBL] [Abstract][Full Text] [Related]
11. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.
Cazzola M; Calzetta L; Rogliani P; Matera MG
Expert Opin Drug Discov; 2016 Jul; 11(7):733-44. PubMed ID: 27169612
[TBL] [Abstract][Full Text] [Related]
12. Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats.
Izikki M; Raffestin B; Klar J; Hatzelmann A; Marx D; Tenor H; Zadigue P; Adnot S; Eddahibi S
J Pharmacol Exp Ther; 2009 Jul; 330(1):54-62. PubMed ID: 19386793
[TBL] [Abstract][Full Text] [Related]
13. Long-chain fatty acid activates hepatocytes through CD36 mediated oxidative stress.
Liu J; Yang P; Zuo G; He S; Tan W; Zhang X; Su C; Zhao L; Wei L; Chen Y; Ruan X; Chen Y
Lipids Health Dis; 2018 Jul; 17(1):153. PubMed ID: 30016988
[TBL] [Abstract][Full Text] [Related]
14. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
15. Expression and activity of phosphodiesterase isoforms during epithelial mesenchymal transition: the role of phosphodiesterase 4.
Kolosionek E; Savai R; Ghofrani HA; Weissmann N; Guenther A; Grimminger F; Seeger W; Banat GA; Schermuly RT; Pullamsetti SS
Mol Biol Cell; 2009 Nov; 20(22):4751-65. PubMed ID: 19759179
[TBL] [Abstract][Full Text] [Related]
16. The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer's Disease: A Preclinical Study in APP/PS1 Transgenic Mice.
Wang H; Zhang FF; Xu Y; Fu HR; Wang XD; Wang L; Chen W; Xu XY; Gao YF; Zhang JG; Zhang HT
Int J Neuropsychopharmacol; 2020 Dec; 23(10):700-711. PubMed ID: 32645141
[TBL] [Abstract][Full Text] [Related]
17. Exploring the Role of Water Molecules in the Ligand Binding Domain of PDE4B and PDE4D: Virtual Screening Based Molecular Docking of Some Active Scaffolds.
Singh P; Mishra M; Agarwal S; Sau S; Iyer AK; Kashaw SK
Curr Comput Aided Drug Des; 2019; 15(4):334-366. PubMed ID: 30394213
[TBL] [Abstract][Full Text] [Related]
18. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
[No Abstract] [Full Text] [Related]
19. GPR40 deficiency is associated with hepatic FAT/CD36 upregulation, steatosis, inflammation, and cell injury in C57BL/6 mice.
Lu Z; Li Y; Syn WK; Li AJ; Ritter WS; Wank SA; Lopes-Virella MF; Huang Y
Am J Physiol Endocrinol Metab; 2021 Jan; 320(1):E30-E42. PubMed ID: 33103454
[TBL] [Abstract][Full Text] [Related]
20. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
